| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 00:32:22 UTC |
|---|
| Update Date | 2021-09-26 22:57:17 UTC |
|---|
| HMDB ID | HMDB0247534 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide |
|---|
| Description | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide, also known as C6-NBD-cer or 6-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproylsphingosine, belongs to the class of organic compounds known as ceramides. These are lipid molecules containing a sphingosine in which the amine group is linked to a fatty acid. Based on a literature review very few articles have been published on N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide. This compound has been identified in human blood as reported by (PMID: 31557052 ). N-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O InChI=1S/C30H49N5O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-27(37)25(23-36)32-28(38)19-16-14-17-22-31-24-20-21-26(35(39)40)30-29(24)33-41-34-30/h15,18,20-21,25,27,31,36-37H,2-14,16-17,19,22-23H2,1H3,(H,32,38) |
|---|
| Synonyms | | Value | Source |
|---|
| 6-N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproylsphingosine | HMDB | | C6-NBD-Cer | HMDB | | C6-NBD-Ceramide | HMDB | | N-(7-(4-Nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine | HMDB | | NBD C6-Cer | HMDB | | NBD-Ceramide | HMDB |
|
|---|
| Chemical Formula | C30H49N5O6 |
|---|
| Average Molecular Weight | 575.751 |
|---|
| Monoisotopic Molecular Weight | 575.368284318 |
|---|
| IUPAC Name | N-(1,3-dihydroxyoctadec-4-en-2-yl)-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide |
|---|
| Traditional Name | N-(1,3-dihydroxyoctadec-4-en-2-yl)-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O |
|---|
| InChI Identifier | InChI=1S/C30H49N5O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-27(37)25(23-36)32-28(38)19-16-14-17-22-31-24-20-21-26(35(39)40)30-29(24)33-41-34-30/h15,18,20-21,25,27,31,36-37H,2-14,16-17,19,22-23H2,1H3,(H,32,38) |
|---|
| InChI Key | HZIRBXILQRLFIK-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as ceramides. These are lipid molecules containing a sphingosine in which the amine group is linked to a fatty acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Sphingolipids |
|---|
| Sub Class | Ceramides |
|---|
| Direct Parent | Ceramides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Ceramide
- Benzoxadiazole
- Nitroaromatic compound
- Secondary aliphatic/aromatic amine
- Fatty amide
- N-acyl-amine
- Fatty acyl
- Benzenoid
- Azole
- Furazan
- Heteroaromatic compound
- Oxadiazole
- Amino acid or derivatives
- Carboxamide group
- C-nitro compound
- Organic nitro compound
- Secondary alcohol
- Secondary carboxylic acid amide
- Organoheterocyclic compound
- Propargyl-type 1,3-dipolar organic compound
- Allyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Secondary amine
- Carboxylic acid derivative
- Organic oxoazanium
- Azacycle
- Organic nitrogen compound
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organonitrogen compound
- Amine
- Carbonyl group
- Organooxygen compound
- Organic oxygen compound
- Organic zwitterion
- Primary alcohol
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross Sections| Predictor | Adduct Type | CCS Value (Å2) | Reference |
|---|
| DeepCCS | [M-2H]- | 266.89 | 30932474 | | DeepCCS | [M+Na]+ | 243.395 | 30932474 |
Predicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 22.472 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.29 minutes | 32390414 |
Predicted Kovats Retention IndicesDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12 | 4890.0 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12 | 4562.6 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12 | 6516.7 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4846.3 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4481.5 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 6246.1 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4697.7 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4380.2 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 5761.8 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4684.6 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4440.0 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 5865.1 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4662.7 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4441.0 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 5905.1 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4726.1 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4484.8 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 5716.9 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4594.7 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 4310.9 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C | 5396.8 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4625.1 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4351.1 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 5481.9 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4610.1 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4393.0 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4 | CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 5599.5 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4626.6 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 4301.4 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C | 5152.3 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 5184.2 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 4804.1 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 5961.1 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 5112.2 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 4711.0 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3 | CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C | 5702.4 | Standard polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 5111.3 | Semi standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4744.1 | Standard non polar | 33892256 | | N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6 | CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 5846.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Positive-QTOF | splash10-000i-0090000000-61acfb5ae30ad3f4c5b0 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Positive-QTOF | splash10-01p9-0090000000-32d518e14392270400a7 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Positive-QTOF | splash10-03gi-0090000000-cd354d61a6e6e3404450 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Positive-QTOF | splash10-0006-0090000000-c40e106c8c737ae3143b | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Positive-QTOF | splash10-0006-0090000000-c40e106c8c737ae3143b | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Positive-QTOF | splash10-001i-0090000000-dc742cc31e628e6617f0 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Negative-QTOF | splash10-004i-0000090000-e1c44efdf24304d6e319 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Negative-QTOF | splash10-004i-0010090000-49766feff9cae7a12916 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Negative-QTOF | splash10-004o-0040090000-d250777c793af0608527 | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|